| Osteoporosis is a systemic bone metabolic disease characterized by the decrease of bone quality, the degeneration of bone microstructure, and the increase of bone fragility. With the advent of the aging society, the incidence of osteoporosis is increasing year by year. Naringenin is a natural exist dihydroflavonoid. Based on the latest national and international research, this article analyzes and discusses the mechanism of naringenin in the treatment of osteoporosis by regulating CD4+ T cells, mimicking the effect of estrogen, inhibiting P38 signaling pathway, and promoting SDF-1/CXCR4 signaling pathway to confirm its effect on inhibiting osteoclast and promoting osteogenesis. It is expected to provide a theoretical basis for the safe, effective, and reasonable development and utilization of naringenin, and to explore a new solution for the prevention and treatment of osteoporosis. |